you are designing a study to evaluate efficacy of new drug km28. your study will compare km28 plus standard care vs standard care alone in decreasing the incidence of recurrent breast cancer. the FDA will approve the new drug if km28 plus standard care reduces the rate of breast cancer recurrence by 40% compared to standard therapy alone. the recurrence rate on standard therapy is found to be 8%. in order for km28 to be approved, what is the maximal incidence of recurrent disease acceptable for women treated with km28 plus standard therapy?
A. 5.2%
B. 4.8%
C. 3.6%
D. 3.2%
E. 2.8%
guys i am not understanding how the relative risk reduction formula is applied here and what is relative risk reduction? can someone explain in detail??
A. 5.2%
B. 4.8%
C. 3.6%
D. 3.2%
E. 2.8%
guys i am not understanding how the relative risk reduction formula is applied here and what is relative risk reduction? can someone explain in detail??